Fundraising Fox
Immunis Biomedical
Irvine, US · 5 known investors
Find your way into Immunis Biomedical
Sign up to see every warm intro you have to Immunis Biomedical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immunis Biomedical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immunis Biomedical develops multi-active biologics based on stem cell-derived secretomes — cell-free therapeutics containing proteins, lipids and growth factors — aimed at treating age-related and immune-related diseases. Its approach targets multiple biological pathways at once rather than a single protein or mechanism.
Founders & leadership
Board
Investors · 5
How we know: Bold Capital Partners's portfolio page · Not right? Tell us
How we know: quadraScope Venture Fund's portfolio page · Not right? Tell us
How we know: Remiges Ventures, Inc.'s portfolio page · funding news · prnewswire.com · Not right? Tell us
Funding
SEC filings, press & company announcements$32.4M disclosed across 2 of 3 rounds · 2022–2026
- Undisclosed amountSeries A First ClosingAug 2022
Remiges Ventures (lead)
Source ↗
▶$12MraisedJun 2026 · 12 investors · BiotechnologyRule 506(b)
- Takahide KodaDirector
- Hans KeirsteadExecutive Officer, Director
- Daniel KraftDirector
- Gabriel NistorExecutive Officer
- Offering amount
- $12M
- Amount sold
- $12M
- Minimum investment
- $50K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.4MraisedOct 2024 · 27 investors · BiotechnologyRule 506(b)
- Gabriel NistorExecutive Officer
- Takahide KodaDirector
- Hans KeirsteadExecutive Officer, Director
- Daniel KraftDirector
- Offering amount
- $25M
- Amount sold
- $20.4M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Immunis Biomedical do?
- Immunis Biomedical develops multi-active biologics based on stem cell-derived secretomes — cell-free therapeutics containing proteins, lipids and growth factors — aimed at treating age-related and immune-related diseases. Its approach targets multiple biological pathways at once rather than a single protein or mechanism.
- Who are Immunis Biomedical's investors?
- Immunis Biomedical's investors include Bold Capital Partners, JLS, Lifespan Vision Ventures, quadraScope Venture Fund, Remiges Ventures, Inc..
- How much funding has Immunis Biomedical raised?
- Immunis Biomedical has disclosed $32.4M raised across 2 of its 3 known rounds.
- Where is Immunis Biomedical headquartered?
- Immunis Biomedical is headquartered in Irvine, US.